The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve ...

The trial is anticipated to enrol 462 subjects and aims to confirm the safety and efficacy of the combination.

Study finds low peripheral blood lymphocyte count at diagnosis predicts worse overall survival in multiple myeloma patients.

Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX® ) and mFOLFOX6 ...

An injectable hydrogel platform shows promise in local immunotherapy for triple-negative breast cancer, enhancing treatment ...

Peripheral blood absolute lymphocyte count at diagnosis is an effective biomarker that can be used to risk-stratify patients with multiple myeloma, according to retrospective study results.Continued ...

The efficacy of immunotherapy against triple-negative breast cancer (TNBC) heavily relies on intratumoral infiltration of ...

Standard induction therapy with lenalidomide, bortezomib, and dexamethasone did not overcome inferior outcomes in patients ...

Researchers conducted a retrospective study to examine the relationship between absolute lymphocyte count (ALC) trajectory and clinical outcomes, and the factors associated with lymphopenia in severe ...